Astra drug tipped as $8-9bn cholesterol winnerAstraZeneca's Crestor is emerging as a potential big winner in the fiercely competitive anti-cholesterol market, with two brokerages on Tuesday hiking sales forecasts for the drug to $8-9 billion. Shares in the Anglo-Swedish group, which h Moreā¦ |